Lantheus Stock Forecast, Price & News

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus or view top-rated stocks.

What stocks does MarketBeat like better than Lantheus?

Wall Street analysts have given Lantheus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lantheus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Lantheus.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Wednesday, July, 28th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.06. The medical equipment provider had revenue of $101.06 million for the quarter, compared to analysts' expectations of $94.60 million. Lantheus had a negative net margin of 7.29% and a positive trailing twelve-month return on equity of 3.51%.
View Lantheus' earnings history.

How has Lantheus' stock price been impacted by Coronavirus?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LNTH shares have increased by 98.0% and is now trading at $26.97.
View which stocks have been most impacted by COVID-19.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its third quarter 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share (EPS) guidance of $0.050-$0.070 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.120. The company issued revenue guidance of $95 million-$100 million, compared to the consensus revenue estimate of $102.83 million.

What price target have analysts set for LNTH?

2 equities research analysts have issued 12-month price objectives for Lantheus' shares. Their forecasts range from $20.00 to $34.00. On average, they expect Lantheus' share price to reach $27.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts' price targets for Lantheus or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:

• Mary Anne Heino, President, Chief Executive Officer & Director
• Robert J. Marshall, Chief Financial Officer & Treasurer
• Simon Robinson, Senior VP-Research & Pharmaceutical Development
• Istvan Molnar, Chief Medical Officer
• Iryna Teslenko, Vice President-Clinical Development

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lantheus' key competitors?

Some companies that are related to Lantheus include Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), Heska (HSKA), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Aspira Women's Health (AWH), OncoCyte (OCX), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), Quotient (QTNT), VolitionRx (VNRX) and Nymox Pharmaceutical (NYMX).
View all of LNTH's competitors.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.02%), Vanguard Group Inc. (6.48%), Price T Rowe Associates Inc. MD (4.19%), State Street Corp (4.01%), Thrivent Financial for Lutherans (3.54%) and Thrivent Financial for Lutherans (3.54%). Company insiders that own Lantheus stock include Andrea Sabens, Etienne Montagut, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends for Lantheus.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Bank of America Corp DE, Goldman Sachs Group Inc., Peregrine Capital Management LLC, Price T Rowe Associates Inc. MD, Boston Partners, Royal Bank of Canada, and Acuitas Investments LLC. Company insiders that have sold Lantheus company stock in the last year include Andrea Sabens, Etienne Montagut, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus or view top insider-selling stocks.

Which major investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Thrivent Financial for Lutherans, Acuitas Investments LLC, Artisan Partners Limited Partnership, Silvercrest Asset Management Group LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Lantheus or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $26.97.

How much money does Lantheus make?

Lantheus has a market capitalization of $1.82 billion and generates $339.41 million in revenue each year. The medical equipment provider earns $-13,470,000.00 in net income (profit) each year or $0.47 on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 595 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

Where are Lantheus' headquarters?

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at (978) 671-8001 or via email at [email protected].